Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?

J Clin Oncol. 2010 Apr 10;28(11):e173-4; author reply e175-6. doi: 10.1200/JCO.2009.26.6148. Epub 2010 Feb 22.

Authors

Chiara Cremolini, Fotios Loupakis, Annamaria Ruzzo, Giuseppe Perrone, Eliana Rulli, Bruno Vincenzi, Giuseppe Tonini, Francesco Graziano, Andrea Onetti Muda, Alfredo Falcone

PMID: 20177018
DOI: 10.1200/JCO.2009.26.6148

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / therapeutic use*
Cetuximab
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / genetics*
Colorectal Neoplasms / metabolism
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / metabolism
Humans
Immunoenzyme Techniques
Mutation / genetics*
Prognosis
Proto-Oncogene Proteins / genetics
Proto-Oncogene Proteins B-raf / genetics
Proto-Oncogene Proteins p21(ras)
Receptors, Androgen / metabolism
Retrospective Studies
ras Proteins / genetics

Substances

AR protein, human
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
KRAS protein, human
Proto-Oncogene Proteins
Receptors, Androgen
ErbB Receptors
BRAF protein, human
Proto-Oncogene Proteins B-raf
Proto-Oncogene Proteins p21(ras)
ras Proteins
Cetuximab